Background/Aims Patients with concurrent type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) face elevated cardiovascular risks. However, optimal oral antidiabetic drug (OAD) selection for this population remains unclear.
Methods Using the Korean National Health Information Database, we conducted a target trial emulation comparing cardiovascular outcomes among patients with T2DM and MASLD (defined by fatty liver index ≥30) who initiated sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, or sulfonylureas with metformin. The primary outcome was major adverse cardiovascular events (MACE), including cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke.
Results Among 71,071 patients (331,726 person-years), SGLT2 inhibitor users experienced a significantly lower MACE risk compared to sulfonylurea users (adjusted subdistribution hazard ratio [aSHR], 0.44; 95% confidence interval [CI], 0.31–0.62). SGLT2 inhibitors also demonstrated a lower MACE risk compared to thiazolidinediones (aSHR, 0.61; 95% CI, 0.39–0.96) and DPP-4 inhibitors (aSHR, 0.59; 95% CI, 0.42–0.83). Cardiovascular mortality risk was notably reduced with SGLT2 inhibitors compared to sulfonylureas (aSHR, 0.13; 95% CI, 0.03–0.50), thiazolidinediones (aSHR, 0.19; 95% CI, 0.04–0.86), and DPP-4 inhibitors (aSHR, 0.22; 95% CI, 0.06–0.84). Mediation analysis revealed that MASLD regression accounted for 8.7% of the total cardiovascular benefit when comparing SGLT2 inhibitors to sulfonylureas.
Conclusions In patients with concurrent T2DM and MASLD, SGLT2 inhibitors demonstrated better cardiovascular outcomes compared to other OADs. These findings suggest that SGLT2 inhibitors may be the preferred OAD choice for cardiovascular risk reduction in this high-risk population.
Seogsong Jeong, Yun Hwan Oh, Seulggie Choi, Jooyoung Chang, Sung Min Kim, Joung Sik Son, Gyeongsil Lee, Joseph C Ahn, Dong Hyeon Lee, Bo Kyung Koo, Won Kim, Sang Min Park
Clin Mol Hepatol 2022;28(3):510-521. Published online March 17, 2022
Background/Aims Accumulating evidence suggests a link between non-alcoholic fatty liver disease (NAFLD) and brain health. However, population-based evidence on the association between NAFLD and dementia remains unclear. This study was conducted to determine the association between NAFLD and incident dementia.
Methods The study population included 608,994 adults aged ≥60 years who underwent health examinations between 2009 and 2010. Data were collected from the Korean National Health Insurance Service database. NAFLD was assessed using the fatty liver index (FLI). A Cox proportional hazards regression model was used to determine the association between NAFLD and dementia.
Results During the 6,495,352 person-years of follow-up, 48,538 participants (8.0%) developed incident dementia. The participants were classified into low (FLI <30), intermediate (FLI ≥30 and <60), and high (FLI ≥60) groups. In the overall study population, the FLI groups were associated with a risk of dementia (P for trend <0.001). After propensity score matching, a low FLI was associated with a reduced risk of dementia (adjusted hazard ration [aHR], 0.96; 95% confidence interval [CI], 0.93–0.98; P=0.002), whereas a high FLI (NAFLD) was associated with an increased risk of dementia (aHR, 1.05; 95% CI, 1.02–1.08; P=0.001). A higher risk of dementia in the high FLI group than in the intermediate FLI group was attributed to Alzheimer’s disease (aHR, 1.04; 95% CI, 1.01–1.07; P=0.004) rather than vascular dementia (aHR, 0.94; 95% CI, 0.75–1.18; P=0.602).
Conclusions NAFLD was associated with an increased risk of dementia, which was attributed to an increased risk of Alzheimer’s disease.
Citations
Citations to this article as recorded by
The Influence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Body Mass Index on the Incidence of Alzheimer Disease: A Nationwide Cohort Study Tae Seop Lim, Seok Jong Chung, Jimin Jeon, Ja Kyung Kim, Jinkwon Kim Gut and Liver.2026; 20(1): 107. CrossRef
Population attributable fractions of a wide range of peripheral diseases for the burden of dementia Zhenhong Deng, Yuxin Yang, Queran Lin, Songhua Xiao, You Zuo, Jinyuan Wang, Yongteng Xu, Honghong Li, Dongshu Xie, Qingyuan Dai, Junfeng Luo, Dame Louise Robinson, Naaheed Mukadam, Yamei Tang Nature Human Behaviour.2026;[Epub] CrossRef
Long-term dementia risk in metabolic dysfunction-associated steatotic liver disease: a population-based study Andreas Bartholdy, Kristine Frøsig Moseholm, Pernille Yde Nielsen, Nicolai J. Wewer Albrechtsen, Lise Lotte Gluud, Majken Karoline Jensen Metabolic Brain Disease.2026;[Epub] CrossRef
Role of metabolic dysfunction and inflammation along the liver–brain axis in animal models with obesity-induced neurodegeneration Evridiki Asimakidou, Eka Norfaishanty Saipuljumri, Chih Hung Lo, Jialiu Zeng Neural Regeneration Research.2025; 20(4): 1069. CrossRef
Associations of metabolic dysfunction-related fatty liver disease and dementia risk: A prospective study based on the UK biobank Chaofan Geng, Peiyang Gao, Yi Tang Archives of Gerontology and Geriatrics.2025; 135: 105845. CrossRef
Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study” Seogsong Jeong, Won Kim, Sang Min Park Clinical and Molecular Hepatology.2025; 31(2): e208. CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease Is Associated With Accelerated Brain Ageing: A Population‐Based Study Jiao Wang, Rongrong Yang, Yuyang Miao, Xinjie Zhang, Stéphanie Paillard‐Borg, Zhongze Fang, Weili Xu Liver International.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study Woo-Young Shin, Eun Seok Kang, Yun Hwan Oh, Meng Sha, Qiang Xia, Seogsong Jeong, Yoosun Cho BMC Gastroenterology.2025;[Epub] CrossRef
A cross sectional study of the diabetes mediated GGT to HDL ratio and cognitive function in older adults Ye Wang, Yanping Mao, Tianmei Xu, Lujie Han, Wenxuan Zhang, Wangdi Sun, Jiaxi Xu, Enyan Yu Scientific Reports.2025;[Epub] CrossRef
Exploring LRP-1 in the liver-brain axis: implications for Alzheimer’s disease Vivek Kumar Sharma Molecular Biology Reports.2025;[Epub] CrossRef
Association between fatty liver index and low back pain: A cross-sectional study from NHANES 1999–2004 Jiangtao Liao, Zhenyu Song, Hao Xu, Yi Li, Dongdong Xu, Hongtao Tian, Zhipeng Dai, Wei Tong Journal of Back and Musculoskeletal Rehabilitation.2025;[Epub] CrossRef
MASLD in the oldest-old: lack of association with cognition or functional autonomy and poor predictive utility of the hepatic steatosis index Maximilian Joseph Brol, Martin Groth, Frank Erhard Uschner, Juliana Stadtmann, Tina Schomacher, Jonel Trebicka, Michael Praktiknjo, Elena Vorona GeroScience.2025;[Epub] CrossRef
Liver integrity and the risk of Alzheimer's disease and related dementias Yifei Lu, James Russell Pike, Ron C. Hoogeveen, Keenan A. Walker, Laura M. Raffield, Elizabeth Selvin, Christy L. Avery, Stephanie M. Engel, Michelle M. Mielke, Tanya Garcia, Priya Palta Alzheimer's & Dementia.2024; 20(3): 1913. CrossRef
Disentangling the contributions of alcohol use disorder and alcohol‐related liver disease towards dementia: A population‐based cohort study Sixian Zhao, Linnea Widman, Hannes Hagström, Ying Shang Addiction.2024; 119(4): 706. CrossRef
The Metabolic Impact of Nonalcoholic Fatty Liver Disease on Cognitive Dysfunction: A Comprehensive Clinical and Pathophysiological Review Mauro Giuffrè, Nicola Merli, Maura Pugliatti, Rita Moretti International Journal of Molecular Sciences.2024; 25(6): 3337. CrossRef
Factor modification in the association between high-density lipoprotein cholesterol and liver cancer risk in a nationwide cohort Su Youn Nam, Junwoo Jo, Won Kee Lee, Chang Min Cho International Journal of Epidemiology.2024;[Epub] CrossRef
Pathology of Amyloid-β (Aβ) Peptide Peripheral Clearance in Alzheimer’s Disease Andrey Tsoy, Bauyrzhan Umbayev, Aliya Kassenova, Bibifatima Kaupbayeva, Sholpan Askarova International Journal of Molecular Sciences.2024; 25(20): 10964. CrossRef
Sex and Gender Differences in Liver Fibrosis: Pathomechanisms and Clinical Outcomes Mohamad Jamalinia, Amedeo Lonardo, Ralf Weiskirchen Fibrosis.2024; 2(4): 10006. CrossRef
Association between composite dietary antioxidant index and fatty liver index among US adults Meng Zheng, Chaochen Li, Jia Fu, Long Bai, Jinghui Dong Frontiers in Nutrition.2024;[Epub] CrossRef
Association between dementia, Alzheimer's disease, and liver cancer: A Mendelian randomization analysis Tianze Li, Jianwei Yi, Xuliang Hu, Huajun Wu, Kai Wang, Binghai Zhou Journal of Alzheimer's Disease Reports.2024; 8(1): 1587. CrossRef
Association of Balance Impairment with Risk of Incident Dementia among Older Adults H.J. Kim, S. Jeong, Yun Hwan Oh, Michelle J. Suh, Jee Young Suh The Journal of Prevention of Alzheimer's Disease.2024; 11(1): 130. CrossRef
Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations” Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(1): 185. CrossRef
Emerging Links between Nonalcoholic Fatty Liver Disease and Neurodegeneration Taylor J. Kelty, Ryan J. Dashek, W. David Arnold, R. Scott Rector Seminars in Liver Disease.2023; 43(01): 077. CrossRef
Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma Seogsong Jeong, Woo-Young Shin, Yun Hwan Oh Frontiers in Endocrinology.2023;[Epub] CrossRef
NAFLD does not increase the risk of incident dementia: A prospective study and meta-analysis Hangkai Huang, Zhening Liu, Jiarong Xie, Chengfu Xu Journal of Psychiatric Research.2023; 161: 435. CrossRef
Effect of Comorbidities on Ten-Year Survival in Patients with Dementia Nida Buawangpong, Kanokporn Pinyopornpanish, Phichayut Phinyo, Wichuda Jiraporncharoen, Chaisiri Angkurawaranon, Atiwat Soontornpun Journal of Alzheimer’s Disease.2023; 94(1): 163. CrossRef
Regulation of mild cognitive impairment associated with liver disease by humoral factors derived from the gastrointestinal tract and MRI research progress: a literature review Tianning Sun, Maohui Feng, Anne Manyande, Hongbing Xiang, Jun Xiong, Zhigang He Frontiers in Neuroscience.2023;[Epub] CrossRef
Impact of ectopic fat on brain structure and cognitive function: A systematic review and meta-analysis from observational studies Zhi-Hui Song, Jing Liu, Xiao-Feng Wang, Rafael Simó, Chao Zhang, Jian-Bo Zhou Frontiers in Neuroendocrinology.2023; 70: 101082. CrossRef
Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes” Seul Ki Han, Soon Koo Baik, Moon Young Kim Clinical and Molecular Hepatology.2023; 29(3): 817. CrossRef
Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes” Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han Clinical and Molecular Hepatology.2023; 29(3): 810. CrossRef
Association of Thyroid Hormone Medication Adherence With Risk of Dementia Saemi Han, Seogsong Jeong, Seulggie Choi, Sun Jae Park, Kyae Hyung Kim, Gyeongsil Lee, Yoosun Cho, Joung Sik Son, Sang Min Park The Journal of Clinical Endocrinology & Metabolism.2023; 109(1): e225. CrossRef
Sex-specific relationship between non-alcoholic fatty liver disease and amyloid-β in cognitively unimpaired individuals Sung Hoon Kang, Heejin Yoo, Bo Kyoung Cheon, Jun Pyo Kim, Hyemin Jang, Hee Jin Kim, Mira Kang, Kyungmi Oh, Seong-Beom Koh, Duk L. Na, Yoosoo Chang, Sang Won Seo Frontiers in Aging Neuroscience.2023;[Epub] CrossRef
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem K. Oz, Ayse Erden, Emily Truong, Ju Dong Yang, Mazen Noureddin, Alina M. Allen, Rohit Loomba, Veeral Ajmera Hepatology.2023; 78(6): 1858. CrossRef
HOMA-IR is an effective biomarker of non-alcoholic fatty liver disease in non-diabetic population Pei Zeng, Xiangsheng Cai, Xiaozhou Yu, Lu Huang, Xi Chen Journal of International Medical Research.2023;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study Joon Ho Moon, Seogsong Jeong, Heejoon Jang, Bo Kyung Koo, Won Kim eClinicalMedicine.2023; 65: 102292. CrossRef
Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia Yohwan Lim, Seogsong Jeong, Myunghee Hong, Hyun Wook Han Reviews in Cardiovascular Medicine.2023;[Epub] CrossRef
Non‐alcoholic fatty liver disease and the risk of dementia—Authors' reply Gi‐Ae Kim, Jae‐Jun Shim Liver International.2022; 42(8): 1914. CrossRef
Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults Byoung Seok Ye Clinical and Molecular Hepatology.2022; 28(3): 481. CrossRef
Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies Li-Yu Lu, Min-You Wu, Yung-Shuo Kao, Cheng-Hsien Hung Clinical and Molecular Hepatology.2022; 28(4): 931. CrossRef
Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies Seogsong Jeong, Won Kim, Sang Min Park Clinical and Molecular Hepatology.2022; 28(4): 933. CrossRef
Dementia and non-alcoholic fatty liver disease – An unprecedented relationship Fakhar Latif, Vania Saqib, Eisha Waqar Annals of Medicine and Surgery.2022; 81: 104359. CrossRef
Risk of dementia or cognitive impairment in non-alcoholic fatty liver disease: A systematic review and meta-analysis Luping Wang, Bowen Sang, Zuyan Zheng Frontiers in Aging Neuroscience.2022;[Epub] CrossRef
First
Prev
